$56.00
Growth Hormone Releasing Hormone (GHRH)
Contents: 5mg of CJC -1295 + DAC
Form: Lyophilized Powder
Purity: ≥ 99% USA Tested, Verified Purity (HPLC Tested)
Verification: Verifiable COA’s (Batch-Matched)
Emerging Research Evidence:
Research on CJC-1295 with DAC examines somatotropic signaling within pre-clinical models, focusing on GHRH-receptor engagement. Scientists utilize the DAC component to study an ‘extended broadcast’ of cellular signals, observing how prolonged timing affects structural-tissue and metabolic pathways. These investigations map adaptive cellular responses and signal coordination in controlled environments, prioritizing pathway data over any clinical application.
Keep product in cool, dark place.
Sold for Research Use Only / Not FDA Regulated
Batch-verified inventory. See 3rd Party COA.
In stock
CJC-1295 with DAC Overview
CJC-1295 with DAC is an investigational signaling peptide used in laboratory models to study sustained growth-hormone-releasing dynamics. Often referred to as the ‘Enduring Signal Pilot,’ this version includes the Drug Affinity Complex (DAC), which researchers use to extend the compounds stability within experimental systems. This allows for the observation of long-range signaling and receptor engagement over much longer periods than standard analogues.
In laboratory settings, this compound is a key tool for mapping neuroendocrine regulation and metabolic coordination. Researchers utilize it to analyze how a ‘steady-state’ signal influences cellular adaptation and structural-tissue pathways. By providing a prolonged window into somatotropic signaling, this peptide helps investigators understand how cells respond to consistent, long-term communication without the rapid degradation seen in traditional models. This product is intended strictly for pre-clinical research and is not approved for human use.
Somatotropic signaling pathway research:
Investigating GHRH-receptor activation, downstream signal transduction, and endocrine-axis regulation in laboratory models
Neuroendocrine regulation studies:
Examining hypothalamic–pituitary signaling coordination and biomarker responses in controlled research systems
Metabolic signaling models:
Studying cellular-energy regulation pathways and metabolic signaling adaptation associated with prolonged peptide activity
Structural-tissue signaling research:
Evaluating cellular-response mechanisms related to connective tissue, muscle, and skeletal signaling pathways in pre-clinical models
Circadian and signaling-timing research:
Investigating relationships between endocrine signaling patterns and circadian-regulated biomarker activity
Current research utilizes CJC-1295 with DAC as a tool for examining extended GHRH-mediated signaling dynamics within neuroendocrine and metabolic research models. Studies focus on pathway regulation, receptor engagement, and biomarker modulation, with all findings remaining pre-clinical and exploratory.
Research-only note: CJC-1295 with DAC is not FDA-approved for therapeutic use; published effects are primarily preclinical and exploratory.
For Research Use Only — Not for Human or Veterinary Use. Not evaluated or approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. All information on this website is provided strictly for laboratory research and educational purposes. Nothing herein constitutes medical, clinical, or legal advice, nor an endorsement of non-laboratory use. Any discussion of specific peptides or potential research findings is informational only and must not be interpreted as guidance for use in or on humans or animals.
